CurTec is known for developing, manufacturing, and distributing high-quality plastic packaging solutions—such as drums, pails, and jars—specifically designed to meet the needs of pharmaceutical, biotechnology, and fine chemical companies. Its products are engineered to protect sensitive, high-value materials from contamination, moisture, and damage during transport and storage, while also complying with rigorous international regulatory standards.

The acquisition by Ampersand aims to accelerate CurTec’s growth and innovation trajectory, particularly as demand for reliable and compliant specialty packaging continues to rise in the life sciences sector. With a focus on delivering value-added solutions, the investment will support CurTec’s expansion into new markets and further development of its manufacturing capabilities.

Ampersand brings decades of experience in scaling healthcare-focused businesses, with a strong track record of strategic partnerships in the pharmaceutical supply chain. The firm stated that it intends to work closely with CurTec’s leadership team to bolster its global presence and invest in new product development and infrastructure enhancements.

Commenting on the acquisition, Ampersand noted CurTec’s strong brand reputation, loyal customer base, and commitment to quality as key drivers behind the deal. The partnership aligns with Ampersand’s strategy of investing in businesses that deliver critical products and services to the pharmaceutical and biotech industries.

The leadership team at CurTec will remain in place post-acquisition, ensuring continuity in operations and customer relationships. This move is expected to provide the company with greater resources and strategic guidance to navigate its next phase of growth.

The deal underscores the increasing investor interest in companies providing essential infrastructure and support solutions within the pharmaceutical manufacturing and logistics ecosystem.